|
Response Biomedical Corporation, based in Burnaby, British Columbia, Canada, develops point-of-care and laboratory medical diagnostics, biodefense, and environmental detection systems and tests. The firm is known for its portable Rapid Analyte Measurement Platform, or RAMP, (R) product line. The RAMP system's fluorescent reader analyzes the contents of disposable test cartridges. Proprietary dyes are used to optimize readings. Results are produced within approximately 15 minutes. The firm has developed West Nile virus environmental tests. It also has developed anthrax, smallpox, ricin, and botulinum toxin on-site detection tests. Response Biomedical has earned ISO 13485:2003 and ISO 9001:2000 certifications. Its immunoassays are marketed to clients across the clinical medicine, pharmaceutical, industrial, and agricultural sectors. Response Biomedical has formed partnerships with Shionogi & Company Limited and 3M Company. The firm also has licensed cardiac marker technology from Roche Diagnostics. Response Biomedical is listed on the Toronto Stock Exchange under the RBM symbol.
|